ArticleFrontiers in endocrinology2019

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.

Maria Fleseriu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.